Yunani - Yunani - Εθνικός Οργανισμός Φαρμάκων

ΦΑΡΑΝ ΑΝΩΝΥΜΗ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΠΑΡΑΓΩΓΗΣ ΚΑΙ ΕΜΠΟΡΙΑΣ ΦΑΡΜΑΚΩΝ Δ.Τ. ΦΑΡΑΝ Α.Β.Ε.Ε. Αχαίας 5 & Τροιζηνίας, 145 64 Ν. Κηφισιά 210.6254175 - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 25mg/cap - lenalidomide 25mg - lenalidomide

Yunani - Yunani - Εθνικός Οργανισμός Φαρμάκων

ΦΑΡΑΝ ΑΝΩΝΥΜΗ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΠΑΡΑΓΩΓΗΣ ΚΑΙ ΕΜΠΟΡΙΑΣ ΦΑΡΜΑΚΩΝ Δ.Τ. ΦΑΡΑΝ Α.Β.Ε.Ε. Αχαίας 5 & Τροιζηνίας, 145 64 Ν. Κηφισιά 210.6254175 - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 15mg/cap - lenalidomide 15mg - lenalidomide

Yunani - Yunani - Εθνικός Οργανισμός Φαρμάκων

ΦΑΡΑΝ ΑΝΩΝΥΜΗ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΠΑΡΑΓΩΓΗΣ ΚΑΙ ΕΜΠΟΡΙΑΣ ΦΑΡΜΑΚΩΝ Δ.Τ. ΦΑΡΑΝ Α.Β.Ε.Ε. Αχαίας 5 & Τροιζηνίας, 145 64 Ν. Κηφισιά 210.6254175 - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 5mg/cap - lenalidomide 5mg - lenalidomide

Yunani - Yunani - Εθνικός Οργανισμός Φαρμάκων

ΦΑΡΑΝ ΑΝΩΝΥΜΗ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΠΑΡΑΓΩΓΗΣ ΚΑΙ ΕΜΠΟΡΙΑΣ ΦΑΡΜΑΚΩΝ Δ.Τ. ΦΑΡΑΝ Α.Β.Ε.Ε. Αχαίας 5 & Τροιζηνίας, 145 64 Ν. Κηφισιά 210.6254175 - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 10mg/cap - lenalidomide 10mg - lenalidomide

Yunani - Yunani - Εθνικός Οργανισμός Φαρμάκων

ΦΑΡΑΝ ΑΝΩΝΥΜΗ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΠΑΡΑΓΩΓΗΣ ΚΑΙ ΕΜΠΟΡΙΑΣ ΦΑΡΜΑΚΩΝ Δ.Τ. ΦΑΡΑΝ Α.Β.Ε.Ε. Αχαίας 5 & Τροιζηνίας, 145 64 Ν. Κηφισιά 210.6254175 - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 20mg/cap - lenalidomide 20mg - lenalidomide

Uni Eropa - Yunani - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - Ανοσοκατασταλτικά - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Uni Eropa - Yunani - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - Ανοσοκατασταλτικά - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 και 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 και 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Yunani - Yunani - Εθνικός Οργανισμός Φαρμάκων

as grindeks, latvia krustpils iela 53, 1057 riga - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 15mg/cap - lenalidomide 18,096mg - lenalidomide

Yunani - Yunani - Εθνικός Οργανισμός Φαρμάκων

as grindeks, latvia krustpils iela 53, 1057 riga - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 20mg/cap - lenalidomide 24,128mg - lenalidomide

Yunani - Yunani - Εθνικός Οργανισμός Φαρμάκων

as grindeks, latvia krustpils iela 53, 1057 riga - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 25mg/cap - lenalidomide 30,16mg - lenalidomide